Edgewise Therapeutics Inc’s filing revealed that its Chief Scientific Officer Russell Alan J unloaded Company’s shares for reported $25520.0 on May 02 ’25. In the deal valued at $16.45 per share,1,551 shares were sold. As a result of this transaction, Russell Alan J now holds 18,521 shares worth roughly $0.27 million.
Then, MOORE JOHN R sold 1,930 shares, generating $31,757 in total proceeds. Upon selling the shares at $16.45, the General Counsel now owns 6,531 shares.
Before that, KOCH KEVIN sold 4,276 shares. Edgewise Therapeutics Inc shares valued at $70,358 were divested by the President and CEO at a price of $16.45 per share. As a result of the transaction, KOCH KEVIN now holds 20,619 shares, worth roughly $0.3 million.
Raymond James initiated its Edgewise Therapeutics Inc [EWTX] rating to a Strong buy in a research note published on July 30, 2025; the price target was $46. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Guggenheim began covering EWTX with “Buy” recommendation on April 30, 2025. Scotiabank revised its rating on April 02, 2025. It rated EWTX as “a Sector perform” which previously was an “a Sector outperform”.
Price Performance Review of EWTX
On Friday, Edgewise Therapeutics Inc [NASDAQ:EWTX] saw its stock jump 0.35% to $14.31. Over the last five days, the stock has gained 1.35%. Edgewise Therapeutics Inc shares have fallen nearly -16.02% since the year began. Nevertheless, the stocks have fallen -46.40% over the past one year. While a 52-week high of $38.12 was reached on 02/06/25, a 52-week low of $10.60 was recorded on 04/07/25.
Levels Of Support And Resistance For EWTX Stock
The 24-hour chart illustrates a support level at 13.98, which if violated will result in even more drops to 13.64. On the upside, there is a resistance level at 14.57. A further resistance level may holdings at 14.82.
How much short interest is there in Edgewise Therapeutics Inc?
A steep rise in short interest was recorded in Edgewise Therapeutics Inc stocks on 2025-07-15, dropping by -1.46 million shares to a total of 11.07 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 12.53 million shares. There was a decline of -13.16%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 07, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $50 price target.
